- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
- Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
- Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
More ▼
Key statistics
On Friday, Seres Therapeutics Inc (MCRB:NSQ) closed at 1.16, 114.81% above the 52 week low of 0.540 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.11 |
---|---|
High | 1.19 |
Low | 1.08 |
Bid | 1.15 |
Offer | 1.16 |
Previous close | 1.11 |
Average volume | 6.28m |
---|---|
Shares outstanding | 151.01m |
Free float | 142.38m |
P/E (TTM) | -- |
Market cap | 175.17m USD |
EPS (TTM) | -0.897 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼